As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

As Hurricane Milton made landfall in Florida Wednesday night, drugmakers, regulators, hospitals and health agencies alike ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair ...

Symbiosis Pharmaceutical Services has shelled out £1.2 million ($1.57 million) to acquire a new manufacturing building at ...

Zevra Therapeutics has partnered with the National Urea Cycle Disorders Foundation to run an awareness campaign designed to ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Through allocations, Baxter is limiting how much customers can order based on their past purchases, medical necessity and ...

Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round ...

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.